|Day Low/High||0.64 / 0.72|
|52 Wk Low/High||0.41 / 1.94|
-- Study Results Further Support Advancement of SYN-005 into Clinical Trials for Treatment and Prevention of Pertussis --
-- Conference Call Scheduled for Thursday, March 2, 2017 at 4:30 p.m. EST --
-- Enrollment in SYN-010 Pivotal Trial Will Be Open to All IBS-C Patients --
-- Presentation Planned for 9:30am (PT), Jan. 9, 2017 at Biotech Showcase in San Francisco --
- Granted Patent Provides Composition of Matter Protection for SYN-005 to at Least 2035 -
-- Conference Call Scheduled for Tuesday, November 1, 2016 at 8:30 a.m. EDT --
-- Funding to Support Ongoing Phase 2b Study to Determine SYN-004's (ribaxamase) Ability to Prevent the Emergence of Antibiotic-Resistance in the Gut Microbiome of Study Participants --
-- Top-line Results Anticipated in the First Quarter of 2017 --
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
These under-$10 stocks are within range of triggering big breakouts. Here's how to trade them now.
Syngenta shares surge after ChemChina takeover receives U.S. security clearance.
U.S. futures up as miners drop with commodities.
-- FDA Provides Company with Recommendation and Guidance for Clinical Study Design for Phase 2b/3 Adaptive Trial --
-- First Granted Patent in Europe Directly Related to Ribaxamase, intended to Prevent C. difficile Infection, Antibiotic-Associated Diarrhea and the Emergence of Antibiotic-Resistant Organisms --
-- Ribaxamase Designed for the Prevention of C. difficile Infection, Antibiotic-Associated Diarrhea & the Emergence of Antibiotic-Resistant Organisms --
-- Phase 2 Clinical Trials Demonstrate Potential of SYN-010 to Reduce Abdominal Pain and Bloating, and Improve Stool Frequency and Quality of Life Scores without Severe Adverse Events in IBS-C Patients --
-- Mark Pimentel, MD, FRCP(C) to Review IBS-C Patient Data from Two SYN-010 Phase 2 Clinical Trials --
-- SYN-004 Degraded IV Ceftriaxone in the Presence of a Proton Pump Inhibitor in the Gastrointestinal Tract without Affecting Antibiotic Levels in the Bloodstream --
-- Company Expands Strategic Partnering Efforts of Late-Stage GI Microbiome-Focused Clinical Programs --
-- Appointment Reflects Company's Late-Stage Clinical Focus and Plans to Prepare for Commercialization --